MTHFD1L and cancer: Furthermore, MTHFD1L effect on the OS of BLCA, HNSC, KIRP, LUAD, and UCEC patients and its hypomethylation have also confirmed MTHFD1L usefulness as a novel potential biomarker of these cancers.